Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net loss	$ (10,285,792)	$ (17,485,559)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	6,398,481	8,225,768
Amortization of debt issuance costs	544,111	553,925
Stock based compensation expense related to issuance of restricted stock	21,954	16,140
Equity in loss of unconsolidated joint venture	607,602
Unrealized derivative gain	218,241	174,001
Derivative fair value adjustment	410,657	(448,294)
Unrealized foreign currency adjustment	(3,108,763)	3,357,638
Changes in operating assets and liabilities:
Other assets, net	354,725	745,672
Purchase of interest rate derivative		(1,126,000)
Settlement of interest rate derivative	(2,030,731)
Accounts payable and accrued liabilities	629,036	510,133
Due to affiliates	4,864,206	7,747,400
Net cash provided by (used in) operating activities	(1,376,273)	2,270,824
Cash flows from investing activities:
Additions to real estate facilities	(5,487,439)	(4,477,240)
Investment in company owned life insurance	(887,387)
Investments in unconsolidated real estate ventures	(2,562,445)	(11,913,676)
Net cash used in investing activities	(8,937,271)	(16,390,916)
Cash flows from financing activities:
Proceeds from issuance of secured debt	173,028,608
Repayment of secured debt	(164,753,059)
Scheduled principal payments of secured debt	(881,005)	(1,397,353)
Debt issuance costs	(1,805,431)
Gross proceeds from issuance of common stock	15,170,192	18,882,572
Offering costs	(1,809,770)	(1,929,609)
Proceeds from issuance of Series C Units	573,002	637,242
Redemption of common stock	(674,336)	(903,578)
Distributions paid to common stockholders	(4,194,779)	(3,687,440)
Distributions paid to noncontrolling interest in our Operating Partnership	(169,886)	(170,591)
Distributions paid to preferred stockholders	(6,236,717)	(6,302,581)
Net cash provided by financing activities	8,246,819	5,128,662
Impact of foreign exchange rate changes on cash and restricted cash	671,828	(709,272)
Net change in cash, cash equivalents and restricted cash	(1,394,897)	(9,700,702)
Cash, cash equivalents and restricted cash, beginning of period	17,565,564	25,708,071
Cash, cash equivalents and restricted cash, end of period	16,170,667	16,007,369
Supplemental disclosures and non-cash transactions:
Cash paid for interest, net of amounts capitalized	6,821,587	8,159,301
Change in offering costs included in accounts payable and accrued liabilities	(882,357)	313,664
Interest rate swap contract in other assets	1,234,991	381,795
Interest rate swap contracts in accounts payable and accrued liabilities	371,144	110,168
Foreign currency hedge contract in other assets	1,190,074
Foreign currency translation adjustment	2,475,802
Deposits applied to investments in unconsolidated real estate ventures		331,335
Issuance of shares pursuant to distribution reinvestment plan	3,271,464	2,713,405
Distributions payable to common and preferred stockholders	4,405,393	4,186,425
Distributions payable to noncontrolling interests in our Operating Partnership	28,029	27,953
Real estate and construction in process in accounts payable and accrued liabilities	1,834,367	1,814,907
Real estate facilities in due to affiliates		104,614
Redemption of common stock in accounts payable and accrued liabilities	$ 3,106,935	$ 391,073